Skip to main content

Ahmed Zakari, MD

Ahmed Zakari, MD

Medical Director of Digestive Tract Cancer, Medical Oncologist.

Cancer

Ahmed Zakari

Overview

Ahmed Zakari, MD, is board-certified in internal medicine, hematology and oncology physician. He was named Chief Fellow at Georgetown University Medical Center, Washington, DC, and is a recipient of the Golden Apple “Best Teacher”Award at Georgetown Medical School. His thesis, “Traumatic Rupture of the Thoracic Aorta,” received honors from all members of the jury. Dr. Zakari is a member of the American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH) and National Arab American Medical Association (NAAMA). Dr. Zakari also serves as the Associate Professor of Internal Medicine at the UCF College of Medicine. He is fluent in Arabic, English and French.

Articles

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

LANCET GASTROENTEROLOGY & HEPATOLOGY

2020

Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment

CYTOTHERAPY

2016

A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

ONCOLOGIST

2016

A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers

CANCER INVESTIGATION

2016

Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

2015

Education & Training

Education

Georgetown University Medical Center, Washington D.C.

Residency

The Brookdale University Hospital, Brooklyn, NY

Fellowship

Georgetown University Medical Center, Washington, D.C.

Specialty

Medical Oncology

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT02923921

AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen (ARTIST 1)

Icon for trial | AM0010-301 AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Contain

The purpose of this study, which involves research, is to determine if an investigational drug, AM0010, in combination with an approved chemotherapy regimen, FOLFOX (oxaliplatin plus 5-fluorouracil (5-FU) plus leucovorin), is s ...